Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUT5 | Q11128 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | DTYMK | P23919 | 2/20 | 0.49 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20325247 | 0.92 | FUT5 (0.50) | FUT5TGM2DTYMKRNASELSTING1 | |
| SCHEMBL18510906 | 0.91 | POLB (0.59) | FUT5DTYMK | |
| SCHEMBL22326689 | 0.91 | FUT5 (0.66) | FUT5TGM2DTYMKRNASELNT5E | |
| SCHEMBL21454900 | 0.91 | FUT5 (0.50) | FUT5TGM2DTYMKRNASELSTING1 | |
| SCHEMBL21454874 | 0.91 | FUT5 (0.50) | FUT5TGM2DTYMKRNASELSTING1 | |
| SCHEMBL20108299 | 0.90 | F2 (0.53) | FUT5TGM2DTYMKSTING1 | |
| SCHEMBL22381773 | 0.90 | FUT5 (0.61) | FUT5TGM2DTYMKRNASELNT5E | |
| SCHEMBL18521985 | 0.90 | FUT5 (0.61) | FUT5TGM2DTYMKRNASELNT5E | |
| SCHEMBL18510894 | 0.90 | FUT5 (0.61) | FUT5TGM2DTYMKRNASELNT5E | |
| SCHEMBL18510908 | 0.90 | FUT5 (0.61) | FUT5TGM2DTYMKRNASELNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | FUT5 4450/4885TGM2 3085/4885DTYMK 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.